Status:
COMPLETED
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
Lead Sponsor:
Alumis Inc
Conditions:
Safety and Tolerability
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit
- Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters
- Other inclusions as specified in the protocol
Exclusion
- Participant has a prior exposure to ESK-001
- Participant has a history of hypersensitivity to any of the ingredients of ESK-001
- Other exclusions as specified in the protocol
Key Trial Info
Start Date :
May 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT05431634
Start Date
May 12 2022
End Date
December 31 2022
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alumis Central site
Glendale, California, United States, 91206